Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The answer is different for everyone, but tracking your response can help you and your clinician find the right plan
Cataract is the leading cause of blindness, accounting for 50% of blindness worldwide [1]
Increased adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during neuropsychiatric drug treatment [36]
In addition to their dramatic effects on blood sugar control and weight loss, GLP-1 receptor agonists (GLP-1 RAs) , the class of drugs including multi-billion blockbusters such as semaglutide (Ozempic) and tirzepatide (Mounjaro, Zepbound), have shown intriguing benefits beyond metabolism
Risks like increased drowsiness, stomach discomfort, blood sugar changes, and effects on heart rate or blood pressure can pose challenges
